Autologous tumor cell–derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion

Feng Wu; Guorong Hu; Lian Chen; Juanjuan Xu; Pingwei Xu; Xuan Wang; Yumei Li; Shuqing Liu; Qi Huang; Jinshuo Fan; Zhilei Lv; Limin Duan; Tingting Liao; Guanghai Yang; Ke Tang; Bi‐Feng Liu; Xiaofei Liao; Xiao‐Nan Tao; Yang Jin

doi:10.1126/scitranslmed.aat5690

Abstract

This is the authors' abstract. We don't add key points for this paper.

cells to release IFN-γ. Our initial experience with ATMPs-MTX in advanced lung cancer with MPE suggests that ATMPs targeting malignant cells and the immunosuppressive microenvironment may be a promising therapeutic platform for treating malignancies.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wu et al. (2019) studied this question.

synapsesocial.com/papers/6a95543bc163d75667fa841d https://doi.org/10.1126/scitranslmed.aat5690

View at Publisher

Ask AI

Bookmark

Share

Autologous tumor cell–derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion

Abstract

Ask about this paper

Discussion

Cite This Study

Autologous tumor cell–derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading